Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29233270 | 0.98 | LMNA (0.40) | LMNAKMT2AMEN1ALDH1A1GAA | |
| SCHEMBL27779786 | 0.81 | CA12 (0.35) | LMNAKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL525285 | 0.81 | LMNA (0.50) | LMNAKMT2AMEN1ALDH1A1GAA | |
| SCHEMBL10510048 | 0.81 | LMNA (0.40) | LMNAKMT2AMEN1ALDH1A1GAA | |
| SCHEMBL5934028 | 0.80 | USP2 (0.35) | LMNAKMT2AALDH1A1MAPTHPGD | |
| SCHEMBL1255349 | 0.79 | ALDH1A1 (0.34) | LMNAKMT2AALDH1A1MAPTHPGD | |
| SCHEMBL28058020 | 0.79 | ANPEP (0.35) | LMNAKMT2AALDH1A1MAPTHPGD | |
| SCHEMBL2898052 | 0.78 | LMNA (0.42) | LMNAKMT2AMEN1ALDH1A1GAA | |
| SCHEMBL8445294 | 0.76 | CA12 (0.31) | LMNAKMT2AALDH1A1MAPTHPGD | |
| SCHEMBL3094796 | 0.75 | KMT2A (0.46) | LMNAKMT2AMEN1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11850294-B2 | Buffered microencapsulated compositions and methods | PREMIER DENTAL PRODUCTS COMPANY (US) | 2023-12-26 | — | — | US | claimed |
| US-20220079849-A1 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | FIDELITY DIRECT LENDING LLC, AS ADMINISTRATIVE AGENT | 2022-03-17 | — | — | US | claimed |
| US-11185480-B2 | Buffered microencapsulated compositions and methods | PREMIER DENTAL PRODUCTS COMPANY (US) | 2021-11-30 | — | — | US | claimed |
| EP-3765036-A1 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | Premier Dental Products Company (US) | 2021-01-20 | — | — | EP | claimed |
| CN-112105367-A | Buffered microcapsule compositions and methods | 第一牙科产品公司 | 2020-12-18 | — | — | CN | claimed |
| US-10688026-B2 | Buffered microencapsulated compositions and methods | PREMIER DENTAL PRODUCTS COMPANY (US) | 2020-06-23 | — | — | US | claimed |
| US-20200016051-A1 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | FIDELITY DIRECT LENDING LLC, AS ADMINISTRATIVE AGENT | 2020-01-16 | — | — | US | claimed |
| WO-2019177927-A1 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | PREMIER DENTAL PRODUCTS COMPANY (US) | 2019-09-19 | — | — | WO | claimed |
| US-20190099335-A1 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | PREMIER DENTAL PRODUCTS COMPANY | 2019-04-04 | — | — | US | claimed |
| US-20180200164-A1 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | FIDELITY DIRECT LENDING LLC, AS ADMINISTRATIVE AGENT | 2018-07-19 | — | — | US | claimed |
| EP-3033790-A1 | FLOW BATTERY AND REGENERATION SYSTEM WITH IMPROVED SAFETY | FTorion, Inc. (US) | 2016-06-22 | — | — | EP | claimed |
| US-20150318568-A1 | High Specific Energy Aqueous Flow Battery | Ftorion, Inc. | 2015-11-05 | — | — | US | claimed |
| US-20140170511-A1 | Flow Battery And Regeneration System With Improved Safety | Ftorion, Inc. (US) | 2014-06-19 | — | — | US | claimed |
| WO-2005073246-A2 | METHOD FOR PREPARING KL4 LUNG SURFACTANT | DISCOVERY LABORATORIES, INC. (US) | 2005-08-11 | — | — | WO | claimed |
| EP-1229940-A1 | TEMPERATURE-CONTROLLED AND PH-DEPENDANT SELF-GELLING BIOPOLYMERIC AQUEOUS SOLUTION | BIO SYNTECH CANADA INC. (CA) | 2002-08-14 | — | — | EP | claimed |
| WO-2001036000-A1 | TEMPERATURE-CONTROLLED AND PH-DEPENDANT SELF-GELLING BIOPOLYMERIC AQUEOUS SOLUTION | BIO SYNTECH CANADA, INC. (CA) | 2001-05-25 | — | — | WO | claimed |
| CN-117940561-A | Liquid transglutaminase enzyme preparation | 天野酶制品株式会社 | 2024-04-26 | — | — | CN | disclosed |
| US-11850294-B2 | Buffered microencapsulated compositions and methods | PREMIER DENTAL PRODUCTS COMPANY (US) | 2023-12-26 | — | — | US | disclosed |
| EP-1229940-A1 | TEMPERATURE-CONTROLLED AND PH-DEPENDANT SELF-GELLING BIOPOLYMERIC AQUEOUS SOLUTION | BIO SYNTECH CANADA INC. (CA) | 2002-08-14 | — | — | EP | disclosed |
| WO-2001036000-A1 | TEMPERATURE-CONTROLLED AND PH-DEPENDANT SELF-GELLING BIOPOLYMERIC AQUEOUS SOLUTION | BIO SYNTECH CANADA, INC. (CA) | 2001-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10688026-B2 | Buffered microencapsulated compositions and methods | LIPA, CHMP4B, APOB | LMNA 492/4885KMT2A 4521/4885MEN1 645/4885 |
| US-11185480-B2 | Buffered microencapsulated compositions and methods | CHMP4B, LIPA, APOB | LMNA 930/4885KMT2A 4734/4885MEN1 708/4885 |
| US-11850294-B2 | Buffered microencapsulated compositions and methods | CHMP4B, LIPA, APOB | LMNA 930/4885KMT2A 4734/4885MEN1 708/4885 |
| US-20220079849-A1 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | CHMP4B, LIPA, APOB | LMNA 930/4885KMT2A 4734/4885MEN1 708/4885 |
| US-20180200164-A1 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | LIPA, CHMP4B, APOB | LMNA 492/4885KMT2A 4521/4885MEN1 645/4885 |
| US-20200016051-A1 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | CHMP4B, LIPA, APOB | LMNA 930/4885KMT2A 4734/4885MEN1 708/4885 |
| US-20190099335-A1 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | LIPA, CHMP4B, APOB | LMNA 706/4885KMT2A 4691/4885MEN1 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.